A photosensitizing fusion protein with targeting capabilities
Related Experiment Video
Updated: Sep 28, 2025

Photoactivated Localization Microscopy with Bimolecular Fluorescence Complementation BiFC-PALM
Published on: December 22, 2015
Stefano Bruno1, Marilena Margiotta1, Marco Cozzolino2,3
1Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy.
Abstract:
The photodynamic treatment for antimicrobial applications or anticancer therapy relies on reactive oxygen species generated by photosensitizing molecules after absorption of visible or near-infrared light. If the photosensitizing molecule is in close vicinity of the microorganism or the malignant cell, a photocytotoxic action is exerted. Therefore, the effectiveness of photosensitizing compounds strongly depends on their capability to target microbial or cancer-specific proteins. In this study, we report on the preparation and preliminary characterization of human recombinant myoglobin fused to the vasoactive intestinal peptide to target vasoactive intestinal peptide receptor (VPAC) receptors. Fe-protoporphyrin IX was replaced by the photosensitizing compound Zn-protoporphyrin IX. Taking advantage of the fluorescence emission by Zn-protoporphyrin IX, we show that the construct can bind prostate cancer cells where the VPAC receptors are expressed.
Insights
Researchers developed a novel photosensitizer by fusing human recombinant myoglobin with vasoactive intestinal peptide. This construct targets prostate cancer cells expressing VPAC receptors, showing potential for targeted photodynamic therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Photodynamic Therapy
Background:
- Photodynamic therapy (PDT) utilizes photosensitizers to generate reactive oxygen species for antimicrobial and anticancer applications.
- PDT effectiveness hinges on photosensitizer specificity for microbial or cancer cells.
- Targeting specific cellular receptors enhances photosensitizer localization and efficacy.
Purpose of the Study:
- To create and characterize a novel photosensitizing construct for targeted cancer therapy.
- To investigate the targeting capability of a human recombinant myoglobin-VPAC receptor construct.
- To evaluate the potential of Zn-protoporphyrin IX as a photosensitizer in this construct.
Main Methods:
- Preparation of human recombinant myoglobin fused to vasoactive intestinal peptide (VIP).
- Incorporation of Zn-protoporphyrin IX as the photosensitizing agent.
- Assessment of construct binding to prostate cancer cells expressing VPAC receptors via fluorescence.
Main Results:
- Successfully synthesized a human recombinant myoglobin-VIP fusion protein.
- Zn-protoporphyrin IX was effectively integrated as the photosensitizer.
- The construct demonstrated specific binding to prostate cancer cells expressing VPAC receptors.
Conclusions:
- The developed myoglobin-VIP-Zn-protoporphyrin IX construct shows promise for targeted photodynamic therapy.
- The construct's ability to bind VPAC-receptor-positive prostate cancer cells is confirmed.
- This approach offers a potential strategy for enhancing the specificity of photodynamic anticancer treatments.
Related Concept Videos
Tagging and Fusion Proteins
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Targeted Cancer Therapies
There are several types of targeted therapies against...

